ADIPOQ and metabolic syndrome: Consequently, therapeutic strategies to manage metabolic syndrome and insulin resistance include raising adiponectin levels through increased release from adipocyte differentiation and gene transcription with the antidiabetic agent thiazolidinedione (TZD) (70, 73).